5-Isothiocyanato-1,2,3,4-tetrahydroquinoline | 1001184-93-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-Isothiocyanato-1,2,3,4-tetrahydroquinoline
• 英文别名: 5-isothiocyanato-1,2,3,4-tetrahydroquinoline
• CAS: 1001184-93-5
• 化学式: C₁₀H₁₀N₂S
• 分子量: 190.269
• InChiKey: ZCEDQENAUONIHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  56.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Isothiocyanato-1,2,3,4-tetrahydroquinoline 、 3-Isopropylpiperazin-1-carboxylic acid (3-fluorophenyl)amide 、 sodium cyanamide 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-[N-cyano-N'-(1,2,3,4-tetrahydroquinolin-5-yl)carbamimidoyl]-N-(3-fluorophenyl)-3-propan-2-ylpiperazine-1-carboxamide
  参考文献：
  名称：

  Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonists

  摘要：

  A novel series of cyanoguanidine-piperazine P2X(7) antagonists were identified and structure-activity relationship (SAR) studies described. Compounds were assayed for activity at human and rat P2X(7) receptors in addition to their ability to inhibit IL-1 beta release from stimulated human whole blood cultures. Compound 27 possesses potent activity (0.12 mu M) in this latter assay and demonstrates moderate clearance in-vivo. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.055

文献信息

• Piperazines as P2X7 antagonists
  申请人：Betschmann Patrick

  公开号：US20080076924A1

  公开（公告）日：2008-03-27

  Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  化合物I式的新型化合物或其药学上可接受的盐、代谢物、异构体、对映体或前药，其中取代基如本文所定义，这些化合物可用作治疗剂。
• [EN] PIPERAZINES AS P2X7 ANTAGONISTS<br/>[FR] PIPÉRAZINES EN TANT QU'ANTAGONISTES DE P2X7
  申请人：ABBOTT LAB

  公开号：WO2008005368A2

  公开（公告）日：2008-01-10

  [EN] Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I), wherein the substituents are as defined herein, which are useful as therapeutic agents.
  [FR] La présente invention concerne de nouveaux composés de formule (I) ou leurs sels pharmaceutiquement acceptables, leurs métabolites, leurs isomères, leurs énantiomères ou leurs promédicaments de formule (i), dans laquelle les substituants sont tels que définis dans la description, qui sont utiles en tant qu'agents thérapeutiques.
• Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonists
  作者：Patrick Betschmann、Brian Bettencourt、Diana Donnelly-Roberts、Michael Friedman、Jonathan George、Gavin Hirst、Nathan Josephsohn、Donald Konopacki、Biqin Li、John Maull、Michael J. Morytko、Nigel StJohn Moore、Marian Namovic、Paul Rafferty、Jose-Andres Salmeron-Garcia、Edit Tarcsa、Lu Wang、Kevin Woller

  DOI：10.1016/j.bmcl.2008.06.055

  日期：2008.7

  A novel series of cyanoguanidine-piperazine P2X(7) antagonists were identified and structure-activity relationship (SAR) studies described. Compounds were assayed for activity at human and rat P2X(7) receptors in addition to their ability to inhibit IL-1 beta release from stimulated human whole blood cultures. Compound 27 possesses potent activity (0.12 mu M) in this latter assay and demonstrates moderate clearance in-vivo. (C) 2008 Elsevier Ltd. All rights reserved.